SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-062068
Filing Date
2023-03-07
Accepted
2023-03-07 07:05:30
Documents
14
Period of Report
2023-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d448387d8k.htm   iXBRL 8-K 25455
2 EX-99.1 d448387dex991.htm EX-99.1 81394
6 GRAPHIC g448387g0306220312684.jpg GRAPHIC 5859
  Complete submission text file 0001193125-23-062068.txt   245894

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20230307.xsd EX-101.SCH 2867
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20230307_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20230307_pre.xml EX-101.PRE 10823
8 EXTRACTED XBRL INSTANCE DOCUMENT d448387d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 23711009
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences